SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:du-23296"
 

Sökning: onr:"swepub:oai:DiVA.org:du-23296" > Population pharmaco...

  • Tchaparian, E. (författare)

Population pharmacokinetics and pharmacodynamics of lumefantrine in young Ugandan children treated with artemether-lumefantrine for uncomplicated malaria

  • Artikel/kapitelEngelska2016

Förlag, utgivningsår, omfång ...

  • 2016-07-28
  • Oxford University Press (OUP),2016
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:du-23296
  • https://urn.kb.se/resolve?urn=urn:nbn:se:du-23296URI
  • https://doi.org/10.1093/infdis/jiw338DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Background. The pharmacokinetics and pharmacodynamics of lumefantrine, a component of the most widely used treatment for malaria, artemether-lumefantrine, has not been adequately characterized in young children. Methods. Capillary whole-blood lumefantrine concentration and treatment outcomes were determined in 105 Ugandan children, ages 6 months to 2 years, who were treated for 249 episodes of Plasmodium falciparum malaria with artemether-lumefantrine. Results. Population pharmacokinetics for lumefantrine used a 2-compartment open model with first-order absorption. Age had a significant positive correlation with bioavailability in a model that included allometric scaling. Children not receiving trimethoprim-sulfamethoxazole with capillary whole blood concentrations <200 ng/mL had a 3-fold higher hazard of 28-day recurrent parasitemia, compared with those with concentrations >200 ng/mL (P =. 0007). However, for children receiving trimethoprim-sulfamethoxazole, the risk of recurrent parasitemia did not differ significantly on the basis of this threshold. Day 3 concentrations were a stronger predictor of 28-day recurrence than day 7 concentrations. Conclusions. We demonstrate that age, in addition to weight, is a determinant of lumefantrine exposure, and in the absence of trimethoprim-sulfamethoxazole, lumefantrine exposure is a determinant of recurrent parasitemia. Exposure levels in children aged 6 months to 2 years was generally lower than levels published for older children and adults. Further refinement of artemether-lumefantrine dosing to improve exposure in infants and very young children may be warranted. © 2016 The Author.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Sambol, N.C. (författare)
  • Arinaitwe, E. (författare)
  • McCormack, S.A. (författare)
  • Bigira, V. (författare)
  • Wanzira, H. (författare)
  • Blessborn, Daniel (författare)
  • Bergqvist, YngveHögskolan Dalarna,Medicinsk vetenskap(Swepub:du)ybq (författare)
  • Aweeka, F.T. (författare)
  • Parikh, S. (författare)
  • Högskolan DalarnaMedicinsk vetenskap (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of Infectious Diseases: Oxford University Press (OUP)214:8, s. 1243-12510022-18991537-6613

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy